Ayahuasca, a traditional hallucinogenic brew from the Amazon Basin, combines the Banisteriopsis caapi vine and Psychotria viridis leaves. Its psychoactive effect relies on DMT, a hallucinogen from Psychotria viridis, which is normally broken down by monoamine oxidase enzymes in the body. Beta-carbolines from Banisteriopsis caapi inhibit these enzymes, allowing DMT to reach the brain and produce vivid hallucinations, emotional sensitivity, and altered consciousness. Scientific research explores its psychological benefits, including emotional healing through introspection and trauma processing, with promising applications for depression, anxiety, and PTSD. The brew may also enhance neural plasticity, helping individuals overcome negative thought patterns.
In a mouse model of depression induced by lipopolysaccharide, ketamine reduced depressive-like behaviors such as increased immobility in the forced swim test and anhedonia, and it also decreased Iba-1 immunoreactivity, a marker of microglial activation. However, ketamine did not reduce the number of microglia or CD11b-positive cells in the hippocampus, nor did it affect the relative weights of the spleen and thymus. These findings suggest that ketamine improves depressive-like behavior and some aspects of neuroinflammation but does not modulate the overall number of microglia or certain immune cell markers in the hippocampus.